Precision Medicine Study on Cardiovascular Disease (PRECISE)

Overview

Cardiovascular diseases are the leading cause of death in China and have become a financial burden on society under the traditional medical model. A new and sustainable medical model is needed to solve this dilemma, for which precision medicine models have great potential. Monogenic cardiovascular disease is the first field to be broken through in precision medicine at this stage, and it is also the field where precision medicine is most likely to be successfully transformed into clinical application, including genetic diagnosis, molecular typing, risk stratification, genetic interruption and individualized treatment.

Study Type

  • Study Type: Observational [Patient Registry]
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: October 10, 2025

Detailed Description

In this study, patients with monogenic cardiovascular disease are recruited prospectively after informed consent was given. The investigator will collect the baseline clinical characteristics of the patients at enrollment, including comprehensive physical examination, laboratory testing of blood and urine, electrocardiography, 24-hour Holter, echocardiography, MRI and other examinations if necessary. The specimens retained include blood, saliva, urine and feces for all patients, and myocardium for patients receive cardio myectomy surgery . Genetic testing will be performed to identify novel disease genes, genetic risk factors and potential therapy targets.

Clinical Trial Outcome Measures

Primary Measures

  • number of participants with cardiovascular deaths
    • Time Frame: an average of 5 years
    • including sudden cardiac death and deaths due to heart failure and stroke.
  • number of participants with all-cause death
    • Time Frame: an average of 5 years.
    • deaths due to all cause.

Secondary Measures

  • number of participants with heart failure
    • Time Frame: an average of 5 years
    • progress to level III or IV in New York Heart Association class.
  • number of participants with stroke
    • Time Frame: an average of 5 years
    • including cerebral infraction and hemorrhage
  • number of participants with malignant arrhythmia
    • Time Frame: an average of 5 years
    • including ventricular fibrillation and ventricular tachycardia

Participating in This Clinical Trial

Inclusion Criteria

  • Patients with monogenic cardiovascular diagnosed according current practice guideline. Exclusion Criteria:

  • Patients who refuse to sign the informed consent or decline follow-up.

Gender Eligibility: All

Minimum Age: N/A

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • China National Center for Cardiovascular Diseases
  • Provider of Information About this Clinical Study
    • Principal Investigator: Lei.Song@NCCD, Principal Investigator – China National Center for Cardiovascular Diseases
  • Overall Official(s)
    • Lei Song, MD. ph.D, Principal Investigator, Fuwai Hospital
  • Overall Contact(s)
    • Lei Song, MD.&ph.D, 86-13810532620, clinicalfw@163.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.